Isentress (raltegravir) is a new class of anti-retroviral for the treatment of HIV.

Isentress is indicated in combination with other anti-retrovirals for treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy


Raltegravir is an integrase inhibitor that inhibits the catalytic activity of integrase, an HIV-encoded enzyme required for viral replication.

Integrase is responsible for inserting the viral DNA into the DNA of the host cell. Inhibition of this enzyme prevents production of new infectious viral particles and further infection of other cells, and results in a reduction in the viral load.

View Isentress drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more